nanoparticles

1102 Words3 Pages

The use of nanoparticles as therapeutic drug agents has garnered much interest for their use in treatment of disease, as well as in vitro and in vivo diagnostics. The attraction of nanoparticles for use in medicine stems from their unique characteristics such as their large surface to mass ratio, quantum properties, and their large functional surface which has the ability to act as compound absorbers and carriers for compounds such as drugs, probes and proteins (De Jong and Borm, 2008). With recent developments in nanotechnology, the use of nanocarriers as drug delivery systems has shown great potential (Wilczewska et al., 2012). Cellular and tissue uptake of optimised nanocarriers is increased in comparison to larger molecules, coupled with the use of organ specific receptors; nanocarriers can be used to effectively enter in much lower doses then used in standard medications (Suri, Fenniri and Singh, 2007). Passive or active mechanism can be employed to create cell specific targeting nanocarriers. Active mechanisms work by conjugation of nanocarriers to affected sites with recognition ligands such as folic acids or peptides etc. Manipulation of the physical environment through changes in pH, temperature or magnetism can also yield the same effects. Passive targeting is achieved through creating, or taking advantage of, increased permeability and retention of vascular structures, in particular the BBB (Lai, Kuo and Leo, 2005. Wilczewska et al., 2012).
Varying types of nanocarriers have been designed to be used as drug delivery systems. Nanocapsules are manufactured vesicle structures that have drug compounds locked into a cavity, which is then surrounded by a polymer membrane or mesoporous silica. The latter is most used in conju...

... middle of paper ...

...nt increase in brain uptake and toxicity against brain tumours expressing p-glycoprotein of nano encapsulated paclitaxel. The nanoparticles were also able to remain intact after crossing into the extracellular space of the brain from the BBB. Toxicity studies performed on the nanoparticles used in Koziara et al. (2004) showed that they had no significant effects on perfusion flow when present in the neurovasculature during in vivo testing. In both in vitro and in vivo studies, the use of these nanoparticles had no effect on BBB integrity, permeability or tight junction proteins (Muldoon et al., 2006. Lockman et al., 2003). Despite these seemingly successful results, the literature available through mediums in the methods section, is lacking in more recent studies using the above nanoparticles; “emulsifying wax/Brij 78” and “Brij 72/Tween 80” loaded with paclitaxel.

More about nanoparticles

Open Document